Se connecter Inscription gratuite

AC Immune SA Transmettre P/E

Quel est le Transmettre P/E de AC Immune SA?

Le Transmettre P/E de AC Immune SA est -4.97

Quelle est la définition de Transmettre P/E?



Le ratio prix à terme/bénéfice est le rapport entre le prix des actions d'une société et son bénéfice par action estimé pour les douze prochains mois.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Transmettre P/E des entreprises dans Health Care secteur sur NASDAQ par rapport à AC Immune SA

Que fait AC Immune SA?

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

Entreprises avec transmettre p/e similaire à AC Immune SA